{
    "organizations": [],
    "uuid": "bd849abc049e4ebbb0621b6b092c5518fe3a733c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vistin-pharma-q4-adjusted-ebitda-l/brief-vistin-pharma-q4-adjusted-ebitda-loss-widens-to-nok-1-6-million-idUSFWN1QH01D",
    "ord_in_thread": 0,
    "title": "BRIEF-Vistin Pharma Q4 Adjusted EBITDA Loss Widens To NOK ‍1.6​ Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - VISTIN PHARMA ASA:\n* Q4 REVENUE NOK ‍41.6​ MILLION VERSUS NOK 32.5 MILLION YEAR AGO\n* Q4 ADJUSTED EBITDA LOSS FROM CONTINUING. OPERATIONS NOK ‍1.6​ MILLION VERSUS LOSS NOK 1.0 MILLION YEAR AGO\n* THE BOARD WILL PROPOSE A DIVIDEND OF NOK 17.1 MILLION (NOK 1.00 PER SHARE) FOR 2017‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-27T14:09:00.000+02:00",
    "crawled": "2018-02-28T13:04:51.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "vistin",
        "pharma",
        "asa",
        "q4",
        "revenue",
        "nok",
        "million",
        "versus",
        "nok",
        "million",
        "year",
        "ago",
        "q4",
        "adjusted",
        "ebitda",
        "loss",
        "continuing",
        "operation",
        "nok",
        "million",
        "versus",
        "loss",
        "nok",
        "million",
        "year",
        "ago",
        "board",
        "propose",
        "dividend",
        "nok",
        "million",
        "nok",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}